Nuclein, LLC, an Austin, Texas-based medical device company, closed a $14m Series B funding round.
The round was led by Trinity Private Equity Group, a Southlake, Texas-based private equity firm.
The company intends to use the funds to to commercialize its novel, hand-held PCR platform designed as a disposable, all-in-one, self-test for infectious disease diagnosis.
Led by Alan Blake, CEO and co-founder, and Dr. Richard Crockett, president and co-founder, Nuclein provides a device that runs real-time PCR, does not require technical expertise to operate, and delivers battery-powered, sample-to-answer results from saliva in under one hour, without the need to mail in a sample. While the Nuclein technology platform has been designed to detect any infectious disease target, the company is currently focusing on COVID-19 to assist with the ongoing pandemic.
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.